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Abstract: Solid lipid nanoparticles (SLNs) comprise a versatile drug delivery system that has been 
developed for the treatment of a variety of diseases. The present study will investigate the 
feasibility of entrapping an active doxorubicin prodrug (a squalenoyl-derivative) in SLNs. The 
doxorubicin derivative-loaded SLNs are spherically shaped, have a mean diameter of 300–400 nm 
and show 85% w/w drug entrapment efficiency. The effects on cell growth of loaded SLNs, free 
doxorubicin and the prodrug have been examined using cytotoxicity and colony-forming assays in 
both human ovarian cancer line A2780 wild-type and doxorubicin-resistant cells. Further 
assessments as to the treatment’s ability to induce cell death by apoptosis have been carried out by 
analyzing annexin-V staining and the activation of caspase-3. The in vitro data demonstrate that 
the delivery of the squalenoyl-doxorubicin derivative by SLNs increases its cytotoxic activity, as 
well as its apoptosis effect. This effect was particularly evident in doxorubicin-resistant cells. 
Keywords: solid lipid nanoparticles; doxorubicin; anticancer agent; nanoassemblies; anticancer 
prodrugs 
 
1. Introduction 
Anthracycline antitumor antibiotics are amongst the most powerful agents for the treatment of 
solid malignancies and can boast a wide range of antitumor activity. Doxorubicin hydrochloride 
(adriamycin) is the most commonly used and is effective in the treatment of carcinomas of the breast, 
lung, thyroid, ovary and soft tissue sarcomas [1]. However, anthracycline therapy is associated  
with significant general organ toxicity and especially myelosuppression, mucositis and cardiac 
toxicity [2]. 
Despite this widespread use of anthracyclines in cancer therapy, their limitations have 
continued to yield significant amounts of research. The main fields of anthracycline research are the 
continuing synthesis of novel anthracycline analogues to reverse drug resistance and reduce 
cardiotoxicity, while improving the delivery of anthracycline drugs is also an active field [3]. An 
important milestone in the field is found in the liposomal formulations Doxil® (Caelyx®) [4] and 
Myocet® [5]. Indeed, doxorubicin-loaded liposomes exhibit efficiencies comparable to those of the 
conventional anthracycline cytostatic agents, but with less cardiotoxicity. Nevertheless, the 
administration of long-circulating liposomes in clinical practice has been associated with 
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palmar-plantar erythrodysesthesia (“hand-foot” syndrome), which may evolve into ulceration and 
epidermal necrosis if the chemotherapy cycle is not delayed [6]. 
Producing prodrug derivatives of doxorubicin is another way to approach improving activity 
against multidrug resistance and/or increasing cardiac tolerability [7]. An interesting doxorubicin 
prodrug, composed of a long lipophilic acyclic isoprenoid chain derived from squalene, has recently 
been created and tested. The conformation of squalene is greatly influenced by solvent polarity,  
so that in polar solvents, such as water, squalene takes a tightly-coiled conformation. This 
squalenoyl derivative of doxorubicin (SQ-Dox) is able to self-organize in water into unique 
“loop-train” elongated nanostructures with high stability [8]. 
The in vivo fate of squalenoyl nanoassemblies (NAs) has recently been described by Couvreur 
and co-workers, who have highlighted the prominent role played by endogenous lipoproteins (LDL) 
in the delivery of squalenoyl NAs in the bloodstream; LDL adsorb onto the NAs, which then 
disassemble, releasing squalenoyl bioconjugates that insert into lipoproteins. Thus, the 
pharmacokinetics and biodistribution are dependent on the LDL route [9,10]. 
Solid lipid nanoparticles (SLNs) are dispersed systems that display sizes ranging from  
1–1000 nm and represent an alternative to polymeric particulate carriers. They are composed of 
physiological or biocompatible lipids or lipid molecules with a history of safe use in therapy, and 
they are generally suitable for intravenous administration [11]. Some authors have found that SLNs,  
which were loaded with doxorubicin, were able to overcome P-glycoprotein (Pgp)-mediated 
multidrug resistance (MDR), both in vitro in resistant leukemia cells and in vivo in the murine 
leukemia mouse model [12,13]. The results suggested that SLNs, which have attracted huge research 
interest from the field of site-specific drug targeting, including brain delivery [14], over the last few 
decades may be able to provide the potential to deliver anticancer drugs for the treatment of  
Pgp-mediated MDR. Indeed, SLNs have been proposed for use as innovative chemotherapeutic 
agent vehicles for experimental glioblastoma multiforme (GBM) treatment, owing to their ability to 
enhance drug uptake by cells and evade the Pgp efflux system. It is well known that SLNs are 
subjected to endocytosis by endothelial cells and that they can also be exploited for passive and,  
if opportunely surface-modified, active targeting to the brain [15]. Indeed, in order to increase cancer 
cell-selective cytotoxicity, one strategy is to surface-engineer drug delivery systems for molecular 
targeting. This strategy, which exploits the differences between cancer cells and healthy cells,  
has recently been adopted for SLN anticancer drug delivery. A folate receptor-targeted lipid 
nanoparticle system has been developed for the delivery of a paclitaxel prodrug [16]. Targeted 
nanoparticles showed elevated antitumor activity in mice bearing the M109 tumor with the marker 
folate receptor. Functionalization with a chimera peptide (Apo E), having a lipophilic moiety and an 
aminoacidic sequence for very low-density lipoprotein (VLDL) receptor binding (ApoE), was 
exploited in order to target SLNs to the VLDL receptor. Enhancement of brain accumulation of 
lipophilic methotrexate prodrug by ApoE-conjugated SLNs was evident especially at longer  
post-administration times, when compared with non-functionalized SLNs [17]. Moreover, as 
described in the literature, loading drugs into SLNs can often lead to their physico-chemical and 
hydrolytic stability being improved, as previously seen in fatty acid SLN-entrapped curcumin [18]. 
Thus, we herein investigate the feasibility of encapsulating the active lipophilic derivative  
SQ-Dox into SLNs in an effort to evaluate the potential of SLNs in releasing the active drug into 
tumor cells and with a view toward conferring improved properties to this anticancer prodrug. The 
lipid moiety in the conjugate can significantly enhance drug loading into the hydrophobic 
components of delivery carriers and thus generates formulations with improved drug loading and  
superior stability [19]. 
The SLNs proposed in this study are prepared using the technique of fatty acid coacervation 
and are stabilized by biodegradable polymers with hydrophilic characteristics, which, once 
adsorbed onto the SLN surface, can prolong in vivo half-life by preventing opsonization. 
For the above-mentioned purpose, SLNs were prepared and extensively characterized with 
regards to their physico-chemical properties, their loading capacity and their cytotoxic potency. 
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2. Materials and Methods 
2.1. Materials 
Doxorubicin and daunorubicin hydrochloride were purchased from APAC Pharmaceutical 
LLC (Columbia, MD, USA). Behenic acid sodium salt (Na-BA) was purchased from Nu-Chek Prep, 
Inc. (Elysian, MN, USA). Squalene, polyvinyl alcohol (PVA 9000), acetonitrile, dimethylformamide, 
dioxane, dimethylsulfoxide, lauric acid, tetrahydrofuran, trifluoroacetic acid and dichloromethane 
were obtained from Sigma (Dorset, UK). Hydrochloric acid, sodium hydroxide and monobasic 
sodium phosphate were obtained from Merck (Darmstadt, Germany). Methanol, thionyl  
chloride, diisopropyl ether, diethyl ether and ethanol were obtained from Carlo Erba (Val De  
Reuil, France). TLC plates and silica gels for chromatography were purchased from Merck, and 
ultrapure (Type 1) water was obtained using a MilliQ system (Millipore, Bedford, MO, USA). 
2,3-bis[2-methoxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide (MTT) and crystal violet 
were purchased from Sigma (Dorset, UK). 
2.2. Methods 
2.2.1. Synthesis of SQ-Dox and Preparation of SQ-Dox NAs 
The synthesis of doxorubicin-14-squalenate [8] proceeded as follows: Trimethyl orthoformate 
(0.20 mL, 1.83 mmol) was added to a solution of daunorubicin hydrochloride (0.20 g, 0.35 mmol), 
dissolved in methanol/1,4-dioxane (1:2 (v/v), 12 mL). The reaction mixture was then stirred at room 
temperature for 20 min. A Br2/CHCl3 (1:9 (w/v), 0.68 mL, 0.43 mmol) solution was then added to this 
mixture. After stirring for 40 min at 30 °C, the resulting solution was poured into dry ether (200 mL), 
and the solid residue was filtered and washed with ether (50 mL × 3). The solid was re-crystallized 
from acetone/ether (1:1 (v/v), 10 mL), filtered off, washed with ether and dried over P2O5 to give  
14-bromo-daunorubicin (0.19 g, 84%), as a red solid with a melting point of 176–177 °C. The  
14-bromo-daunorubicin (415.6 mg, 0.625 mmol) and 1,1′,2-tris-norsqualenoic acid (500 mg,  
1.25 mmol) were dissolved in acetone (50 mL) under inert argon atmosphere. Potassium carbonate 
(260 mg, 1.875 mmol) was then added, and the reaction mixture was stirred at room temperature for 
48 h (dark). The solvent was evaporated and the crude product purified using silica gel flash column 
chromatography (95:5, CH2Cl2–MeOH), to give a red powder (249.5 mg, 43%). The target compound, 
dissolved in anhydrous THF (240 mg in 2 mL), was then converted to its hydrochloride salt via the 
addition of an anhydrous, titrated 4 M solution of HCl in dioxane (1.2 eq., 0.075 mL) and subjecting it 
to stirring at −20 °C for 2 h. The solvents were then removed, and the red solid product was further 
purified by washing with diisopropyl ether. The yield of doxorubicin-14 squalenate hydrochloride 
(SQ-Dox) was 171.9 mg (70%). The purity of SQ-Dox was checked by silica TLC-eluted  
CH2Cl2: MeOH:HCOOH:H2O (88:15:2:1, Rf 0.5) and by HPLC-MS. 1H NMR (methanol-d4): 8.02 (d, 
1H, H-3), 7.87 (d, 1H, H-1), 7.70 (t, 1H, H-2), 5.46 (s, 1H, H-10), 5.3–5.25 (m, 2H, H-14a, H-14b) and 
5.20 [s, 5H, C(SQ-H)], 5.19 (s, 1H, H-7), 4.15 (q, 1H, H-50), 4.01 (s, 3H, OCH3), 3.74 (m, 2H, H-30,  
H-40), 3.24 (d, 1H, H-10), 3.00 (d, 1H, H-10), 2.43 (m, 1H, H-8), 2.29 and 2.35 (s, 4H, CH2 SQ), 2.13 (m, 
1H, H-8), 2.03 (m, 16H, CH2 SQ), 1.97 (m, 1H, H-20), 1.82 (m, 1H, H-20), 1.71 (m, 18H, C(SQ)-CH3), 
1.29 (d, 3H, CH3); HPLC: the Waters XTerra RP-18 column was eluted with water, methanol (starting 
at 50:50 for 7 min, after which the gradient was moved to 100% methanol, 15 min), plus formic acid 
0.05%. Elution time was 28.95 min. The elution was monitored at 234 and 480 nm using a Waters 
2996 Photodiode Array detector. ESI MS (Waters micromass), m/z calculated for [C54H71NO12 + H]+: 
927.14. Found 927.2 (MH+). Elemental analysis calculated: C 67.38%, H 7.54%, Cl 3.68%, N 1.46%. 
Found: C 67.42%, H 7.61%, Cl 3.67%, N 1.42%. 
SQ-Dox NAs were prepared using the nanoprecipitation method, and the freshly prepared 
formulation was used for further in vitro studies. Briefly, 500 μL of the tetrahydrofuran solution of 
SQ-Dox (4 mg/mL) were added dropwise under stirring (500 rpm) to 1 mL of a 1 mM phosphate 
saline buffer of pH 7.4. The precipitation of the SQ-Dox NAs occurred spontaneously. The organic 
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solvent was completely evaporated under vacuum to obtain an aqueous suspension of pure SQ-Dox 
NAs (final concentration 2 mg/mL). SQ-Dox NAs were stored at 4 °C. 
2.2.2. Preparation SQ-Dox-Loaded SLNs 
Appropriate amounts of Na-BA (1% w/w) and PVA 9000 (2% and 3% w/w in the SLN1 and SLN2 
preparations, respectively), used as polymeric steric stabilizers [20], were dispersed in 5 mL 
deionized water, and the mixture was then heated under stirring (300 rpm), at just above the Krafft 
point of Na-BA (75 °C), to obtain a clear micellar solution. A selected acidifying solution (100 μL 1 M 
NaH2PO4 + 160 μL 1 M HCl) was then added dropwise until pH 3.5–4.0 was reached. The obtained 
suspension was then cooled in a water bath under stirring at 300 rpm until the SLNs completely 
precipitated. Drug-loaded SLNs were prepared as described for blank SLNs (empty SLNs), plus the 
addition of 200 μL of a SQ-Dox solution (10 mg/mL in methanol:2-propanol 2:1 v/v), directly into the 
2.5-mL SLN suspension, which was heated to just above the melting point of BA (80 °C). The sample 
was then cooled in a water bath under stirring at 300 rpm until a temperature of 15 °C was reached. 
In order to remove traces of any non-entrapped drug, SLN preparations were purified by gel 
centrifugation on Bio-gel P-6DG (pore size 90–180 μm, nominal exclusion limit 6000 Da). All 
procedures were performed under a horizontal laminar flow hood, and SLN preparations were 
stored at 4 °C. 
2.2.3. NA and SLN Characterization 
2.2.3.1. Size and Zeta Potential Measurements 
The average diameter and polydispersity index (PDI) of the NAs and SLNs were determined 
using quasi-elastic light scattering (QELS) and a nanosizer (Brookhaven, NY, USA), at a fixed angle 
of 90° and a temperature of 25 °C. The various dispersions (NAs or SLNs) were 1:20 diluted with 
MilliQ water before analysis. SLNs and NAs were also diluted with the various growth media 
described later in the cytotoxicity studies. Each value reported is the average of five measurements. 
In order to determine electrophoretic mobility, NA and SLN samples were opportunely diluted 
with 0.1 mM KCl and placed in the electrophoretic cell of the nanosizer, where an electric field of 
15.24 V/cm was established. Each sample was analyzed in triplicate. Zeta potential values were 
calculated using the Smoluchowski equation. 
Particle size, polydispersity index and zeta potential were determined 1 h after suspension 
preparation. For size stability studies vs. time, samples were stored at 4 °C. All data were 
determined in triplicate.  
Optical microscopy, equipped with a fluorescent lamp (Leica DM 2500, Solms, Germany) at 
630× magnification, was used to determine whether the SQ-Dox derivative was effectively localized 
within the SLN dispersion. 
Entrapment efficiency (EE%) determination was performed as follows: a 1-mL SLN suspension 
was centrifuged for 15 min at 62,000× g, and the precipitate was then washed twice with 1 mL 
ethanol:water (30:70 v/v), to eliminate the adsorbed drug. The solid residue was dissolved in 
dimethylsulfoxide:dichloromethane (1:1 v/v). Then, 0.1 mL water were added in order to precipitate 
the lipid matrix, and the supernatant was injected into a HPLC for SQ-Dox derivative determination, 
as described later. The SQ-Dox EE% was calculated as the ratio between the amount of drug in the 
SLNs and that in the starting micellar solution × 100. 
Loading capacity (DL%) is the amount of drug loaded per unit weight of SLNs, indicated as the 
percentage of mass. 
2.2.3.2. Differential Scanning Calorimetry  
DSC studies were performed using a Perkin Elmer DSC-7 and Pyris Version 3.7.1 software.  
The DSC measurements were carried out on the following samples: unloaded SLNs, SQ-Dox loaded 
SLNs and free SQ-Dox. A weighed amount of each lyophilized sample was transferred to a 
calorimetric pan, hermetically sealed and submitted to DSC analysis. Heating curves were recorded 
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by transferring an amount of the various samples to aluminum pans with a scan rate of 10 °C/min at 
a temperature range of 40 °C to 250 °C using an empty aluminum pan as the reference. 
2.2.3.3. Atomic Force Microscopy  
AFM observation was carried out using a Park XE 100 atomic force microscope (Park 
Instruments, Sunnyvale, CA, USA). AFM images were obtained via measurement of the interaction 
forces between the tip (Mikromash NSC15) and the sample surface. The experiments were 
conducted at room temperature (20 °C), at atmospheric pressure (760 mmHg), and were operated in 
non-contact mode, in which the space between the tip and the sample was between 10 and 100 Å, 
and the total force was very low. The resonant frequencies of this cantilever were found to be around 
250 kHz. The samples were diluted in water (1:10 v/v), immediately before analyses, to provide a less 
sticky fluid to analyze. SLN droplets of constant volume (20 μL) were deposited onto a small mica 
disk with a diameter of 1 cm. The water excess was removed using a paper filter after 2 min. 
2.2.3.4. SQ-Dox Stability Evaluation: HPLC Analysis 
In order to define the stability of SQ-Dox after SLN preparation and storage, HPLC analyses 
were performed using the YL9100 HPLC system equipped with a YL9110 quaternary pump, a YL 
9101 vacuum degasser and a YL 9160 PDA detector linked to YL-Clarity software Version 3.0.4.444 
for data analysis (Young Lin, Hogye-dong, 258 Anyang, Korea). A LiChrospher 100 RP8 5 μm 80 × 
4.6 mm column (Merck) was eluted with acetonitrile (A) and phosphate buffer (50 mM at pH = 2 
adjusted by HCl (0.01 N) (B) according to the following gradient system (30% A–70% B to 90% A–10% 
B in 15 min at a flow rate of 1 mL/min; total run of 25 min). The UV-Vis detector was set at λ 480 nm. 
Rt was 16 min. 
2.2.4. In Vitro Biological Evaluations 
2.2.4.1. Cell Cultures 
Cells and culture conditions: A2780 (human ovarian carcinoma) and A2780 Dox-resistant  
(A2780 res) cell lines were obtained from ATCC (Milan, Italy). The tumor cell lines were grown as 
monolayers in culture dishes in RPMI 1640 medium (Invitrogen, Burlington, ON, Canada), 
supplemented with 10% penicillin-streptomycin (Invitrogen) and 10% fetal calf serum (Euroclone, 
Milan, Italy), in a humidified atmosphere at 37 °C and 5% CO2. To maintain resistance, A2780  
Dox-resistant cell medium was supplemented with 1 μg/mL of Dox once a week. 
2.2.4.2. Cell Viability Assay 
Cells (3 × 103/well) were seeded in 96-well plates and incubated at 37 °C, in 5% CO2, for 24 h. 
Cells were then either treated with varying concentrations of Dox, SQ-Dox, SQ-Dox-loaded SLNs 
(10−8–10−5 M as Dox) or empty SLNs. After 72 h of incubation, the number of viable cells was 
evaluated using the 2,3-bis[2-methoxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide 
(MTT) inner salt reagent at 570 nm, as described in the manufacturer’s protocol. The controls (i.e., 
cells that had received no drug) were normalized to 100%, and the readings from the treated cells 
were expressed as % of viability inhibition. Six replicates were used to determine each data point, 
and five different experiments were performed. 
2.2.4.3. Colony-Forming Assay 
A2780 and A2780 res cells (3 × 103/well) were seeded into six-well plates and treated with either 
Dox, SQ-Dox, SQ-Dox-loaded SLNs (10−9–10−5 M as Dox) or empty SLNs. The medium was changed 
after 72 h, and cells were cultured for an additional 10 days. Cells were subsequently fixed and 
stained with a solution of 80% crystal violet and 20% methanol. Colonies were then photographed 
and counted using Gel Doc equipment (Bio-Rad Laboratories, Milan, Italy). The cells were then 
perfectly washed, and 30% acetic acid was added to induce the complete dissolution of the crystal 
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violet. Absorbance was recorded at 595 nm using a 96-well-plate ELISA reader. Five different 
experiments were performed. 
2.2.4.4. Cell Death Analysis 
A2780 and A2780 res cell lines were either treated with a variety of concentrations of Dox,  
SQ-Dox, SQ-Dox-loaded SLNs, empty SLNs or left untreated. Cells were harvested 72 h after 
treatment, washed with PBS and subsequently resuspended in annexin-V binding buffer (BD 
Biosciences, San Jose, CA, USA), supplemented with 1:100 APC-conjugated annexin-V (BD 
Biosciences). Cells were analyzed using a FACS Calibur cytometer (BD, Bioscience). Subsequently, 
caspase-3 activity was assessed in cell lysates using a fluorometric assay (MBL, Watertown, MA, 
USA), according to the manufacturer’s instructions. 
2.2.5. Statistical Analysis 
Data were expressed as the mean ± SEM (standard error mean = standard deviation/number of 
replicates). Statistical analyses were performed using GraphPad Prism 3.0 software (San Diego, CA, 
USA), as well as the one-way ANOVA and Dunnett tests. Values of p < 0.05 were considered 
statistically significant. 
3. Results 
3.1. NA and SLN Preparation and Characterization 
The nanoformulations containing SQ-Dox were prepared as described above. SLNs were 
prepared using the coacervation method, based on the precipitation of fatty acids. Precipitation 
occurred when the pH of a fatty acid-alkaline salt micellar solution was lowered by acidification in 
the presence of an appropriate polymeric stabilizer, which was able to confer hydrophilicity to the 
SLN surface [21]. Behenic acid sodium salt was chosen as the component of the lipid matrix as it has 
not shown any evidence of detectable cytotoxicity [22]. SQ-Dox NAs were prepared by the 
nanoprecipitation process obtained by solvent displacement. All the formulations were prepared 
and checked in triplicate. The mean diameters (± standard error, SE), PDI and zeta potential of SLNs 
and SQ-Dox NAs were checked first using quasi-elastic light scattering (Table 1). SQ-Dox 
nanostructures displayed a low mean diameter, which was smaller than that of empty SLNs. The 
incorporation of the drug into SLNs increased the mean diameter of lipid nanoparticles to the  
300–400-nm range. Even if the zeta potential values fall down into the neutrality range of charged 
systems, small differences probably due to surface modifications can be observed. The zeta potential 
of the empty SLNs prepared by coacervation is around 0 mV [18], because polyvinyl alcohol (PVA 
9000), which was used as a stabilizer, locates itself externally, partially screening the surface  
charge [21]. In the SQ-Dox-loaded SLNs, the zeta potential value also depended on the drug 
arrangement in the lipid matrix [23], meaning that the slightly positive value shown by SQ-Dox 
SLNs can be due to the partial arrangement of the drug on the outside of the SLN surface. The slight 
difference between zeta potential of SLN1 and SLN2 can be due to the different amount of PVA 
(higher in SLN2) partially shielding the SLN surface. Anyway, these small differences probably do 
not contribute to significant variation of SLN stability. 
The stability of the suspensions was checked by measuring mean size, both after long storage 
times (up to 45 days), at 4 °C in water and in cell medium (RPMI 1640 supplemented with 10% 
penicillin-streptomycin (Invitrogen) and 10% fetal calf serum) for incubation times up to 72 h. 
Particle diameters were measured in water at a range of times, up to 45 days, and were practically 
unmodified. Growth media do not seem to influence SLN dimensions, as all formulations 
maintained their size (±5%), while the size of SQ-Dox NAs was significantly affected after 72 h at 
37 °C in cell medium (Table 1). The stability of the active agent in each phase of the SLN preparation 
and storage was assessed by HPLC analysis. No significant amounts of SQ-Dox degradation 
products were observed (data not shown). 
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Table 1. Physicochemical characteristics of squalenoyl derivative of doxorubicin (SQ-Dox) 
nanoassemblies (NAs) and of empty and SQ-Dox-loaded solid lipid nanoparticles (SLNs).  
The stability was assessed via the measurement of particle size after long storage times in water at  
4 °C and in complete cell medium (72 h). 
Samples Mean Diameter (nm) ± S.E. PDI Zeta Potential (mV) ± S.E EE% ± S.E
Mean Diameter (nm) ± S.E.
T = 15 d T = 45 d 
T = 72 h 
Cell Medium
SQ-Dox NAs 130 ± 17 0.086 12.12 ± 1.52 - 150 ± 7 160 ± 18 450 ± 35 
Empty SLNs 272 ± 6 0.108 −2.20 ± 0.84 - 280 ± 9 282 ± 12 270 ± 12 
SQ-Dox SLN1 400 ± 10 0.227 10.34 ± 2.47 85 ± 3 420 ± 5 394 ± 6 400 ± 7 
SQ-Dox SLN2 305 ± 6 0.200 2.57 ± 0.43 50 ± 3 348 ± 5 355 ± 5 320 ± 8 
The amount of SQ-Dox in SLNs, as prepared by dispersion in 2% w/w (SQ-Dox SLN1) and  
3% w/w (SQ-Dox SLN2) PVA 9000 aqueous solution, is expressed as EE%. This value was calculated 
after SLN centrifugation and washing with ethanol:water 30:70 v/v. Encapsulation efficiency was 
significantly influenced by PVA 9000 content; when the stabilizer percentage was increased from  
2%–3% w/w, a decrease in drug entrapment from 85–50 ± 3% (w/w) was noted (Table 1). This was 
probably caused by PVA 9000 forming micelles in the aqueous phase, which were able to solubilize 
SQ-Dox. Nevertheless, SLNs showed good SQ-Dox loading capacity ranging from 4.0% for SQ-Dox 
SLN2 to 6.8% for SQ-Dox SLN1. Due to higher drug loading, the SLN1 formulation was chosen for 
further characterizations and tests on cancer cell lines. 
The behavior of SQ-Dox was evaluated at the same temperature and pH conditions as the SLN 
preparation, since this derivative is able to self-assemble in water to form NAs. The obtained 
particles showed micrometric dimensions under QELS measurement, and large aggregates were 
observed under the microscope, meaning that the concomitant self-assembly of the conjugate can be 
ruled out. 
SLN microphotographs are reported in Figure 1. Only particles with a mean diameter higher 
than 500 nm were clearly visualized, according to optical microscopy resolution power. Anyway,  
the presence of drug crystals was excluded by observation under polarized light. Moreover,  
when SQ-Dox was submitted to the same procedure used for SLN preparation in the absence of the 
lipid matrix, no self-assembled structures were evidenced. The observation of SLN suspensions 
under the optical microscope, although not a conclusive test for the physico-chemical 
characterization of SLNs, confirmed their formation. The possible presence of micellar structures 
was not detectable with optical microscopy, owing to the small size of micelles. The use of 
fluorescent light allowed SQ-Dox association with SLNs to be identified; dispersions of fluorescent 
SLNs were observed in both suspensions. 
 
Figure 1. Optical microscopy images of SQ-Dox-loaded SLNs, Formulation 1. 
We move now to DSC measurements. A thermogram of SQ-Dox NAs reveals a broadened 
transition peak at a temperature (Tm) of around 153 °C (Table 2). A strongly lowered transition peak 
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was observed, with a shift at lower temperature (about 141 °C), when the conjugate was 
incorporated into SLNs. This behavior is probably due to conjugate incorporation into the lipid 
matrix and to interactions with the nanoparticle structure. Moreover, thermograms of SLNs reveal a 
sharp melting peak at 75 °C, which is a little lower than that of raw BA. 
Table 2. Thermodynamic data determined from the DSC of the NAs and SLNs. 
Tonset (°C) Tm (°C) ΔH (KJ/g) 
SQ-Dox NAs 148.09 153.47 141.460 
SQ-Dox SLN1 139.28 141.18 49.960 
According to Siekmann and Westesen [24], melting point decreases in SLN colloidal systems 
can be caused by the colloidal dimensions of the particles and, in particular, their high 
surface-to-volume ratio. The melting point falls when bulk matrix material is turned into SLNs;  
the presence of impurities, surfactants and stabilizers could also have an influence on this 
phenomenon [25]. 
The BA-SLNs’ peak was also maintained in the presence of the conjugate, which indicates that 
the nanoparticle structure was unmodified (data not shown). 
The morphology of SQ-Dox SLN1 was investigated using AFM. A topography AFM image is 
presented in Figure 2. The structures evident in the image confirm the size measured by QELS, 
although the presence of a certain degree of aggregation can be observed. We also noted the surface 
roughness of the SLNs. Further investigation with cryo-transmission electron microscopy could be 
useful to clarify the morphology. 
 
Figure 2. Underwater AFM images, performed in non-contact mode, of the SQ-Dox SLN1 
formulation after sample deposition on a mica support: topography on the left and amplitude on the 
right. 
3.2. In Vitro Evaluations 
3.2.1. SQ-Dox NA and SQ-Dox SLN1 Inhibition in Cell Proliferation Tests 
We compared the ability of Dox, SQ-Dox NAs, SQ-Dox SLN1 and empty SLNs to inhibit the 
growth of A2780 and A2780 res cells. Cells were cultured either in the presence or the absence of 
titrated amounts (10−8–10−5 M as Dox equivalent) of each sample for 72 h, and the number of viable 
cells was then assessed using the MTT assay. 
Figure 3 shows the inhibition of cell proliferation induced by Dox, SQ-Dox NAs and SQ-Dox 
SLN1. The effect was concentration dependent, with an inhibition of 70–90% observed at the highest 
concentrations. While Dox is more efficient than SQ-Dox, SQ-Dox SLN1 induces an inhibitory effect 
that is similar to that of Dox in the A2780 cell line (Panel A). A2780 res cell proliferation was 
naturally affected only by the higher concentrations of Dox and SQ-Dox, which induced an 
inhibition of around 50%, while SQ-Dox SLN1 also remained effective at a concentration of 10−6 M 
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(Panel B). Cells treated with empty SLNs displayed the same effects as those experienced by 
untreated cells. 
Clonogenic survival assays were performed to validate these findings (Figure 4). Cells were 
seeded onto six-well plates and treated with titrated amounts (10−8–10–5 M as Dox equivalent) of each 
sample. The culture medium was changed after 72 h, and cells were cultured for an additional  
10 days in the absence of the compounds. The results showed that treatment with SQ-Dox SLN1 
inhibited the A2780 cell line’s ability to form colonies, similarly to Dox. However, SQ-Dox was 
slightly less efficient at the lowest concentrations (Panel A). SQ-Dox SLN1 was even more effective 
in the A2780 res cell line, proving that Dox is slowly released from the SLNs, which protects the drug 
from degradation and prevents efflux pump extrusion (Panel B). 
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Figure 3. Inhibition of A2780 (A) and A2780 res (resistant) (B) cell proliferation following Dox,  
SQ-Dox NAs and SQ-Dox SLN1 treatment. Cells were treated with increasing concentrations 
(expressed as Dox equivalent) of compounds and empty SLNs for 72 h. Six replicates were used to 
determine each data point, and five different experiments were performed. One-way ANOVA and 
Dunnett’s test revealed statistically-significance differences (** p < 0.01) between the effects caused to 
A2780 res cells of the loaded SLNs vs. SQ-Dox treatments. 
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Figure 4. The effects of Dox, SQ-Dox NAs and SQ-Dox SLN1 treatment on cell clonogenicity were 
tested by a colony-forming assay of A2780 (A) and A2780 res (B) cell lines. One-way ANOVA and 
Dunnett’s tests were performed on five different experiments, revealing statistically-significance 
differences (* p < 0.05; ** p < 0.01) in SQ-Dox SLN1 vs. Dox-treated cells. 
3.2.2. SQ-Dox NAs and SQ-Dox SLN1 Increase Caspase-3 Activity In Vitro 
The levels of cell death, evaluated by the activation of caspase-3, in A2780 and A2780 res cell 
lines were evaluated after treatment with Dox, SQ-Dox NAs, SQ-Dox SLN1 and empty SLNs at a 
variety of concentrations (Figure 5). Treatment with SQ-Dox NAs and SQ-Dox SLN1, at all 
concentrations tested, significantly increased caspase-3 activity in A2780 cells, as compared to  
Dox-treated cells. However, the SQ-Dox SLN1 formulation showed the highest efficacy, compared to 
SQ-Dox cells treated at the same concentrations, at all the concentrations tested. Notably, SQ-Dox 
SLN1 maintained its efficacy compared to SQ-Dox at 10−9 M (Panel A). 
SQ-Dox and loaded SLNs significantly increased caspase-3 activity in the A2780 res cell line, 
compared to Dox-treated cells, at all the concentrations tested. However, the loaded SLN 
Nanomaterials 2018, 8, 110  11 of 16 
 
formulation exerted a higher efficacy, at a concentration of 10−5 M, than that exerted on 
SQ-Dox-treated cells at the same concentration (Panel B). Treatment with empty SLNs displayed the 
same effects as those observed in untreated cells. 
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Figure 5. Levels of caspase-3 activity after Dox, SQ-Dox NAs and SQ-Dox SLN1 treatment. Caspase-3 
activity was evaluated in A2780 (A) and A2780 res (B) cell lines cultured for 72 h in either the 
presence or absence of Dox, SQ-Dox NAs, SQ-Dox SLN1 or empty SLNs. Results are expressed as % 
of relative caspase activity, calculated as follows: (result displayed by each treatment/result 
displayed by untreated cells). * p < 0.05 and ** p < 0.01, vs. Dox-treated cells at the same 
concentrations, from three independent experiments. 
3.2.3. SQ-Dox NAs and SQ-Dox SLN1; Levels of Annexin-V 
A further assessment of SQ-Dox SLN1’s ability to induce cell death was obtained by analyzing 
annexin-V staining, for the detection of both apoptotic and necrotic cells, in A2780 and A2780 res 
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cells cultured in the presence and absence of titrated amounts of Dox and SQ-Dox NAs, as well as 
loaded and empty SLNs for 72 h (Figure 6). 
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Figure 6. Levels of annexin-V-positive cells after Dox, SQ-Dox NAs, SQ-Dox SLN1 treatment. 
Annexin-V activity was evaluated in A2780 (A) and A2780 res (B) cell lines cultured for 72 h in either 
the presence or absence of Dox, SQ-Dox NAs, SQ-Dox SLN1 or empty SLNs. * p < 0.05 and ** p < 0.01, 
vs. Dox-treated cells at the same concentrations; # p < 0.05 and ## p < 0.01 vs. SQ-Dox-treated cells at 
the same concentrations, from three independent experiments. 
The results obtained show that SQ-Dox NAs and SQ-Dox SLN1 induced higher annexin-V 
staining in the A2780 cell line than free Dox (Panel A). Moreover, loaded SLNs were significantly 
more effective than SQ-Dox at increasing annexin levels at all tested concentrations, which is in line 
with the findings obtained from caspase-3 analyses. 
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SQ-Dox NAs and SQ-Dox SLN1 similarly induced higher annexin-V staining in the A2780 res 
cell line than free Dox at the highest concentrations. However, only 10−5 M SQ-Dox SLNs reported a 
significant increase in annexin-V levels, when compared to SQ-Dox NAs at the same concentrations 
(Panel B). 
4. Discussion 
SLNs are a category of versatile drug delivery systems that have been studied in the biomedical 
field for several years. One of the main reasons for the fast development of SLNs is their ability to 
effectively deliver both lipophilic and even smaller nanoparticles in such a way as to combine,  
as frequently reported in literature, therapeutic and diagnostic behavior. From an industrial point of 
view, other advantages can be found in the fact that their preparation often does not require organic 
solvents, that they can be easily sterilized and that the production of these lipid nanocarriers can be 
easily scaled up [26]. In particular, the preparation of SLNs using the fatty acid coacervation 
technique (FACT), which allows the incorporation of drugs in a micellar solution of FA alkaline salts, 
does not require complex equipment and can be easily moved for industrial application [27]. This 
method is based on the slow interaction between a micellar solution of a sodium salt of a fatty acid 
and an acid solution (coacervation solution), in the presence of a proper amphiphilic polymeric 
stabilizing agent; the sudden lowering of pH causes SLN precipitation. Among the various fatty 
acids available, behenic acid was chosen as the lipid matrix, because, contrary to stearic and palmitic 
acid, it does not cause any detectable cytotoxicity in a number cell lines [28]. This method has been 
widely used to entrap both lipophilic anticancer agents (directly) and hydrophilic drugs, such as 
Dox, after the formation of hydrophobic ion pairs [29]. To further improve stability, some Dox 
lipophilic prodrugs have recently been prepared and efficiently incorporated in SLNs [21]. 
The squalenoyl derivative used in this work is a rather singular lipophilic Dox prodrug,  
which has led to the formation of small-sized nanoassemblies, via the use of the solvent 
displacement technique and the squalenoylation approach, a strategy that has led to several active 
nanoassemblies being prepared and a variety of different agents being co-precipitated (theranostic 
approach) [30,31]. These are soft structures that can be sensitive to a wide range of parameters, 
meaning that, in order to evaluate the in vitro and in vivo stability improvements in a squalenoyl 
derivative, it was necessary to efficiently entrap it in phospholipid vesicles (liposomes) [32]. This 
approach, which combines the intrinsic properties and stability of SLNs with the potency of SQ-Dox, 
will, of course, be interesting for many, even if significant differences in drug loading must be taken 
into account for the following in vivo tests.  
The hydrophobic core of SLNs can easily accommodate the Dox prodrug. The preparation 
procedure, which operates at a temperature that is kept slightly higher than the Krafft point of the 
chosen BA for a few seconds, does not degrade the prodrug structure and allows significant drug 
loading to occur. The incorporation of SQ-Dox into the SLN core has been proven by DSC, while size 
and structure have been confirmed by DLS and AFM analysis. Stability has been confirmed in water 
for all formulations (SLNs and SQ-Dox NAs). However, NAs showed significant aggregation under 
conditions resembling cell culture tests. 
Activity on resistant ovarian cancer cells was higher for SQ-Dox than it was for Dox, which is 
similar to results published by Maksimenko et al., who reported in vitro and in vivo activity [8]. 
However, an experiment on the same cell line, but which possessed induced resistance to Dox, 
highlights the role played by SLNs in more efficiently delivering SQ-Dox to resistant cells (clone). 
Hallmarks of apoptosis induction were performed in order to evaluate the apoptotic effect, caspase-3 
activation and annexin-V levels of the treatments [33]. Cells that had undergone early apoptosis 
were precisely tagged in the annexin-V test, which confirmed the earlier results of SQ-Dox’s 
increased efficiency compared to the free drug, both in normal and resistant A2780 lines [8]. 
SQ-Dox appeared to be more active than other hydrophobic Dox prodrugs [21], but its 
improved activity and physical stability against resistant cell lines were more evident when it was 
incorporated into the SLN core. Moreover, association with lipidic carriers allows SQ-Dox to enter 
cells even with a low level of LDL receptor expression, as in the case of A2780 Dox-resistant cells [34], 
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and to display significant anticancer efficacy. Indeed, squalenoyl derivative NAs have recently 
shown that they are preferentially uptaken by cancer cells with a high LDL-accumulating character, 
which results in higher activity [9,10]. 
The observation that the inhibition detected in the clonogenic assay was substantially higher 
than that detected in the cytotoxicity assay suggests that cells, which were still viable after 72 h of 
treatment, were severely damaged and unable to proliferate in the clonogenic assay, which partially 
confirms the slow release of the Dox ester from SLNs. Our cell culture viability tests and apoptosis 
assays show that SQ-Dox NAs displayed antiproliferative and cytotoxic effects that are comparable 
to those of native Dox. This was proven with the high activity of apoptotic mediators, such as  
caspase-3 and, even more clearly, with annexin-V. 
When all the results presented herein are taken as a whole, it appears clear that SQ-Dox SLNs 
can partially inhibit the proliferation of a resistant cell line by overcoming MDR, thanks to the fact 
that the entrapped drug is protected from the Pgp efflux mechanism of a cell. Nevertheless, further 
investigation into other resistant cancer cell lines, using a variety of LDL receptor expressions,  
is needed to confirm this hypothesis. 
Acknowledgments: We are grateful to Ettore Bernardi for AFM measurements, to Konstantin Chegaev for 
generously providing daunorubicin intermediate, and to Dale JM Lawson for language correction. This work 
was supported by MIUR, University of Turin Fondi Ricerca Locale (ex-60%) and Fondazione Cassa di 
Risparmio di Torino, Project 2015/2707. 
Author Contributions: Barbara Stella performed the synthesis of the doxorubicin prodrug, its characterization 
and data analysis. Elena Peira and Marina Gallarate designed and performed the SLN formulations and their 
characterizations. Luigi Battaglia performed the DSC measurements. Chiara Dianzani, Casimiro Luca Gigliotti 
and Elena Boggio designed and performed all the cell evaluations. Umberto Dianzani designed the in vitro 
experiments and data analysis. Franco Dosio, Barbara Stella and Elena Peira were responsible for designing the 
nanostructures and writing the manuscript. 
Conflicts of Interest: The authors declare no conflicts of interest. 
References 
1. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular Advances and 
Pharmacologic Developments in Antitumor Activity and Cardiotoxicity. Pharmacol. Rev. 2004, 56, 185–229. 
2. Gianni, L.; Herman, E.H.; Lipshultz, S.E.; Minotti, G.; Sarvazyan, N.; Sawyer, D.B. Anthracycline 
cardiotoxicity: From bench to bedside. J. Clin. Oncol. 2008, 26, 3777–3784. 
3. Nadas, J.; Sun, D. Anthracyclines as effective anticancer drugs. Expert Opin. Drug Discov. 2006, 1, 549–568. 
4. Barenholz, Y. Doxil®—The first FDA-approved nano-drug: Lessons learned. J. Control. Release 2012, 160, 
117–134. 
5. Batist, G.; Ramakrishnan, G.; Rao, C.S.; Chandrasekharan, A.; Gutheil, J.; Guthrie, T.; Shah, P.; Khojasteh, 
A.; Nair, M.K.; et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated 
doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a 
randomized, multicenter trial of metastatic breast cancer. J. Clin. Oncol. 2001, 19, 1444–1454. 
6. Kubicka-Wołkowska, J.; Kędzierska, M.; Lisik-Habib, M.; Potemski, P. Skin toxicity in a patient with 
ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature. 
Oncol. Lett. 2016, 12, 5332–5334. 
7. Arpicco, S.; Dosio, F.; Stella, B.; Cattel, L. Anticancer prodrugs: An overview of major strategies and recent 
developments. Curr. Top. Med. Chem. 2011, 11, 2346–2381. 
8. Maksimenko, A.; Dosio, F.; Mougin, J.; Ferrero, A.; Wack, S.; Reddy, L.H.; Weyn, A.-A.; Lepeltier, E.; 
Bourgaux, C.; Stella, B.; et al. A unique squalenoylated and nonpegylated doxorubicin nanomedicine with 
systemic long-circulating properties and anticancer activity. Proc. Natl. Acad. Sci. USA 2014, 111, E217–
E226. 
9. Sobot, D.; Mura, S.; Yesylevskyy, S.O.; Dalbin, L.; Cayre, F.; Bort, G.; Mougin, J.; Desmaële, D.; 
Lepetre-Mouelhi, S.; Pieters, G.; et al. Conjugation of squalene to gemcitabine as unique approach 
exploiting endogenous lipoproteins for drug delivery. Nat. Commun. 2017, 8, 15678. 
Nanomaterials 2018, 8, 110  15 of 16 
 
10. Sobot, D.; Mura, S.; Rouquette, M.; Vukosavljevic, B.; Cayre, F.; Buchy, E.; Pieters, G.; Garcia-Argote, S.; 
Windbergs, M.; Desmaële, D.; et al. Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated 
Drugs to LDL-Accumulating Cancer Cells. Mol. Ther. 2017, 25, 1596–1605. 
11. Patro, N.M.; Devi, K.; Pai, R.S.; Suresh, S. Evaluation of bioavailability, efficacy, and safety profile of 
doxorubicin-loaded solid lipid nanoparticles. J. Nanopart. Res. 2013, 15, 2124. 
12. Ma, P.; Mumper, R.J. Anthracycline nano-delivery systems to overcome multiple drug resistance: A 
comprehensive review. Nano Today 2013, 8, 313–331. 
13. Kang, K.W.; Chun, M.-K.; Kim, O.; Subedi, R.K.; Ahn, S.-G.; Yoon, J.-H.; Choi, H.-K. Doxorubicin-loaded 
solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomed. Nanotechnol. Biol. 
Med. 2010, 6, 210–213. 
14. Laquintana, V.; Trapani, A.; Denora, N.; Wang, F.; Gallo, J.M.; Trapani, G. New strategies to deliver 
anticancer drugs to brain tumors. Expert Opin. Drug Deliv. 2009, 6, 1017–1032. 
15. Battaglia, L.; Muntoni, E.; Chirio, D.; Peira, E.; Annovazzi, L.; Schiffer, D.; Mellai, M.; Riganti, C.; Salaroglio, 
I.C.; Lanotte, M.; et al. Solid lipid nanoparticles by coacervation loaded with a methotrexate prodrug: 
Preliminary study for glioma treatment. Nanomedicine 2017, 12, 639–656. 
16. Stevens, P.J.; Sekido, M.; Lee, R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic 
paclitaxel prodrug. Pharm. Res. 2004, 21, 2153–2157. 
17. Neves, A.R.; Queiroz, J.F.; Lima, S.A.C.; Reis, S. Apo E-Functionalization of Solid Lipid Nanoparticles 
Enhances Brain Drug Delivery: Uptake Mechanism and Transport Pathways. Bioconj. Chem. 2017, 28, 995–
1004. 
18. Chirio, D.; Gallarate, M.; Peira, E.; Battaglia, L.; Serpe, L.; Trotta, M. Formulation of curcumin-loaded solid 
lipid nanoparticles produced by fatty acids coacervation technique. J. Microencapsul. 2011, 28, 537–548. 
19. Irby, D.; Du, C.; Li, F. Lipid-Drug Conjugate for Enhancing Drug Delivery. Mol. Pharm. 2017, 14, 1325–
1338. 
20. Scholes, P.D.; Coombes, A.G.A.; Illum, L.; Davis, S.S.; Watts, J.F.; Ustariz, C.; Vert, M.; Davies, M.C. 
Detection and determination of surface levels of poloxamer and PVA surfactant on biodegradable 
nanospheres using SSIMS and XPS. J. Control. Release 1999, 59, 261–278. 
21. Peira, E.; Chirio, D.; Battaglia, L.; Barge, A.; Chegaev, K.; Gigliotti, C.L.; Ferrara, B.; Dianzani, C.; Gallarate, 
M. Solid lipid nanoparticles carrying lipophilic derivatives of doxorubicin: Preparation, characterization, 
and in vitro cytotoxicity studies. J. Microencapsul. 2016, 33, 381–390. 
22. Gallarate, M.; Serpe, L.; Foglietta, F.; Zara, G.P.; Giordano, S.; Peira, E.; Chirio, D.; Battaglia, L. Solid lipid 
nanoparticles loaded with fluorescent-labelled cyclosporine A: Anti-inflammatory activity in vitro. Protein 
Pept. Lett. 2014, 21, 1157–1162. 
23. Kushwaha, A.K.; Vuddanda, P.R.; Karunanidhi, P.; Singh, S.K.; Singh, S. Development and Evaluation of 
Solid Lipid Nanoparticles of Raloxifene Hydrochloride for Enhanced Bioavailability. Biomed. Res. Int. 2013, 
2013, 584549. 
24. Siekmann, B.; Westesen, K. Thermoanalysis of the recrystallization process of melt-homogenized glyceride 
nanoparticles. Colloids Surf. B Biointerfaces 1994, 3, 159–175. 
25. Hou, D.; Xie, C.; Huang, K.; Zhu, C. The production and characteristics of solid lipid nanoparticles (SLNs). 
Biomaterials 2003, 24, 1781–1785. 
26. Tapeinos, C.; Battaglini, M.; Ciofani, G. Advances in the design of solid lipid nanoparticles and 
nanostructured lipid carriers for targeting brain diseases. J. Control. Release 2017, 264 (Suppl. C), 306–332. 
27. Battaglia, L.; Gallarate, M.; Cavalli, R.; Trotta, M. Solid lipid nanoparticles produced through a 
coacervation method. J. Microencapsul. 2010, 27, 78–85. 
28. Battaglia, L.; Gallarate, M.; Peira, E.; Chirio, D.; Muntoni, E.; Biasibetti, E.; Capucchio, M.T.; Valazza, A.; 
Panciani, P.P.; Lanotte, M.; et al. Solid lipid nanoparticles for potential doxorubicin delivery in 
glioblastoma treatment: Preliminary in vitro studies. J. Pharm. Sci. 2014, 103, 2157–2165. 
29. Battaglia, L.; Gallarate, M. Lipid nanoparticles: State of the art, new preparation methods and challenges in 
drug delivery. Expert Opin. Drug Deliv. 2012, 9, 497–508. 
30. Fumagalli, G.; Stella, B.; Pastushenko, I.; Ricci, F.; Christodoulou, M.S.; Damia, G.; Mazza, D.; Arpicco, S.; 
Giannini, C.; Morosi, L.; et al. Heteronanoparticles by self-Assembly of Doxorubicin and Cyclopamine 
Conjugates. ACS Med. Chem. Lett. 2017, 8, 953–957. 
Nanomaterials 2018, 8, 110  16 of 16 
 
31. Arias, J.L.; Reddy, L.H.; Othman, M.; Gillet, B.; Desmaële, D.; Zouhiri, F.; Dosio, F.; Gref, R.; Couvreur, P. 
Squalene based nanocomposites: A new platform for the design of multifunctional pharmaceutical 
theragnostics. ACS Nano 2011, 5, 1513–1521. 
32. Pili, B.; Reddy, L.H.; Bourgaux, C.; Lepêtre-Mouelhi, S.; Desmaële, D.; Couvreur, P. Liposomal 
squalenoyl-gemcitabine: Formulation, characterization and anticancer activity evaluation. Nanoscale 2010, 
2, 1521–1526. 
33. Wlodkowic, D.; Skommer, J.; Darzynkiewicz, Z. Flow cytometry-based apoptosis detection. Methods Mol. 
Biol. 2009, 559, doi:10.1007/978-1-60327-017-5_2. 
34. Mazzoni, A.; Trave, F. Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive 
and multidrug-resistant human ovarian cancer cells. Oncol. Res. 1993, 5, 75–82. 
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons by 
Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). 
